Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007783 | 0.83 | CYP4F2 (0.48) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL2998944 | 0.80 | FFAR1 (0.45) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL3011586 | 0.78 | MAOA (0.49) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL2998991 | 0.75 | FFAR1 (0.42) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL3006786 | 0.72 | FFAR1 (0.40) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL3006050 | 0.72 | FFAR1 (0.42) | ALDH1A1FFAR1BCHEMGLL | |
| SCHEMBL3000996 | 0.71 | GAA (0.43) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL21922352 | 0.70 | GAA (0.53) | GAAALDH1A1FFAR1LMNAHTT | |
| SCHEMBL2997842 | 0.67 | NPC1 (0.40) | FFAR1CA1CA2CA9BCHE | |
| SCHEMBL5691423 | 0.67 | AR (0.56) | FFAR1ALOX5CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | GAA 892/4885ALDH1A1 3642/4885FFAR1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.